Background: Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of recurrent respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation. Aim: To compare the clinical efficacy of oral montelukast with inhaled budesonide as controller medication in mild persistent childhood asthma. Methods: 54 Children of both genders aged 3 to 12 years, diagnosed as mild persistent childhood asthma in OPD and in pediatric indoor admissions at the tertiary care Hospital in Mumbai were enrolled in this randomized prospective parallelgroup comparative study. 28 (51.9%) patients of group A were started on Oral montelukast & 26 (48.1%) of group B were started on inhaled budesonide. Results: Amongst patients of Group A, 9 were asymptomatic & 19 were symptomatic at 4 weeks of treatment.10 were asymptomatic & 18 were symptomatic at 3 months of treatment. P-Value was 0.09 suggesting no significant change/improvement in control of asthma symptoms at 3months than at 4 weeks in children treated with oral montelukast. Out of 26 patients of Group B, 6 were asymptomatic & 20 were symptomatic at 4 weeks of treatment. 17 were asymptomatic & 9 were symptomatic at 3 months of treatment. P-Value was 0.046 suggesting a statistically significant improvement in control of asthma symptoms at 3 months than at 4 weeks in children treated with inhaled budesonide. Conclusion: More children on inhaled budesonide were controlled on their asthma symptoms, required significantly less reliever medications, had lesser episodes of night awakening due to asthma symptoms and had improvement in their daytime symptoms and activity than those on oral montelukast.
Introduction:
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of recurrent respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation 1 . IgE is the antibody responsible for activation of allergic reactions in the pathogenesis of allergic diseases leading to the development and persistence of inflammation. Mast cellshave large number of IgE receptors that release a wide variety of mediators to initiate acute bronchospasm and proinflammatory cytokines to perpetuate underlying airway inflammation when activated 2 .
Less inflammation typically leads to better asthma control, with fewer exacerbations and decreased need for quick-reliever asthma medications. However, exacerbations can still occur 2 . Out of India's 1.31 billion people, about 6% of children and 2% of adults have asthma 3 .
One study using data from the third National Family Health Survey (NFHS 3) found the prevalence of selfreported asthma symptoms to be 1.9%. 4 . The burden of asthma is immense, with more than 300 million individuals currently suffering from asthma worldwide, about 1/10th of which are living in India. The prevalence of asthma has been estimated to range 3-38% in children, being the commonest chronic disorder amongst them 5 . Asthma accounts for 1 in 250 deaths across the globe, however, most of these deaths are preventable with appropriate management 3, 6 .
The recommended dose of montelukast is 4 mg/day for children under 5 years, 5 mg/day between 6 to 14 years and 10 mg/day over 14 years, preferentially at night. Leukotriene Receptor Antagonists (LTRA), according to most studies, are well-tolerated. Side effects include headache, otitis, abdominal pain, pharyngitis, urticaria and nausea 7 .
Montelukast is a safe drug with modest benefits in bronchial asthma. It is useful in mild persistent asthma where ICS administration may-be impractical due to compliance issues, and also in patients with comorbidities like allergic rhinitis. It is also found to decrease the episodes of viral-induced wheeze in young children 8 . Montelukast was demonstrated to be not inferior to fluticasone in increasing the percentage of Rescue Free Days (RFDs) among 6-to 14year-old patients with mild asthma 8 . Inhaled budesonide also caused a dose-dependent reduction in lower leg growth, but this only reached significance at the 800 mg/day dose 9 . In this study, we tried to compare the clinical efficacy of oral montelukast with Inhaled budesonide considering symptom control as main outcome 10 .
Aim
To compare the clinical efficacy of oral montelukast with inhaled budesonide as controller medication in mild persistent childhood asthma.
Materials and Methods
This randomized prospective parallel-group comparative study was carried out from January 2017 to October 2018. Sixty children of both genders, between 3-12 years age recently diagnosed as mild persistent asthma that attended Asthma clinic or were admitted in the pediatric ward of a tertiary care hospital in Mumbai participated in the study. Institutional ethics committee approval was taken. Written informed consent was taken from the parents.
Out of the 60 enrolled study subjects; randomization in group A or group B was done by numbering the subjects serially & dividing into odd & even numbers with odd numbers being included in group A & even numbers in group B. Group A: 30 patients were given montelukast 4 mg (<5 years) or 5 mg (>5 years) tablet as once a day in the evening for 3 months. Group B: 30 patients were given inhaled budesonide 100 mcg 1 puff twice a day with MDI and spacer with a mask in children below 5 years & with/without a mask in children above 5 years of age for 3months. Out of 60 patients enrolled for study, Group A (n=30) had 2 dropouts (2 lost to follow-up) and group B (n=30) had 4 dropouts (2 lost to follow-up, 2 Poor compliance to treatment) There were total 6 dropouts; hence 54 patients were included in the final study.
Inclusion criteria
 Children of both genders of age 3 to 12 years diagnosed as mild persistent childhood asthma in OPD and in paediatric indoor admissions.
Exclusion criteria
 Any child with associated acute or chronic respiratory illness  Children lost to follow-up  Children with poor/non-compliance with treatment including incorrect inhalational technique  Children with other comorbid conditions like heart, kidney, liver, CNS disorders
Study technique
A detailed history of patients including chief complaints, comorbidities, symptom frequency, family history of asthma or other allergic disorders, perinatal history, family history and allergen history was recorded. Clinical examination and baseline investigations like complete blood count with the absolute eosinophilic count, pulmonary function test (in children more than 6 years of age) were done. Clinical categorization of asthma was done as per severity and children with mild persistent childhood asthma meeting inclusion criteria were included in the study.
Statistical analysis
 Pearson's chi-square test was applied to test the relationship between categorized independent and dependent variables.  Mean and standard deviations were calculated  Unpaired T-test was performed to test the relationship between independent variables.  Microsoft Excel was used to enter & code the data, SPSS 21.0 was used to decode & analyze data.  The p-value (significance) of < 0.05 is deemed statistically significant.
Definition:
Mild persistent asthma is defined as the asthmatic daytime attack occurs>2/week, but<1/day and night time attack >2/month, FEV1 or PEF>80% of predicted and PEF variability 20-30%. (Table 5 ).  At 3 months of treatment, 15(53.6%) patients in group A had daytime symptoms more than twice/week against 7 (26.9%) in group B. With a pvalue of 0.057, there was no statistically significant difference in daytime symptoms between the two treatment groups at 3 months of treatment.  At 3 months of treatment, 15(53.6%) patients in group A had night awakening due to asthma symptoms as against 6 (23.1%) in group B. Thus, children in Group B had lesser episodes of night awakening due to asthma symptoms at 3 months follow up as compared to that in Group A (p=0.028-Significant).  At 3 months of treatment, 17 (60.7%) patients in group A needed reliever more than twice/week against 7 (26.9%) in group B. This shows that children in Group B required fewer reliever medications at 3 months follow up as compared to those in Group A (p=0.016-Significant).  At 3 months of treatment, 6 (21.4%) patients in group A had a limitation of activity as against 1 (3.8%) in group B, with a p-value of 0.102, there was no statistically significant difference in activity limitation between the two treatment groups at 3 months of treatment.  During 3 months of treatment, 2 (7.1%) patients in group A had acute severe exacerbation requiring step-up of treatment as against 1 (3.8%) in group B. With a p-value of 0.100, there was no statistically significant difference in the incidence of acute severe exacerbations between two treatment groups.
Results
 At 3 months following regular treatment: 10 (35.7%) patients were controlled in group A as against 17 (65.4%) in group B. 7 (25.0%) patients were partially controlled in group A as against 5 (19.2%) in group B. 11 (39.3%) patients were uncontrolled in group A as against 4 (15.4%) in group B. A p-value of 0.069, suggested statistically nonsignificant difference in the control status between two groups at 3 months of treatment. However, in terms of percentage, more number of children in Group B were controlled on their asthma symptoms.  In 14 patients out of 28 in group A, symptoms were triggered by viral URTI whereas 11 out of 26 patients in group B had this triggering factor. At 4 weeks out of these cases,8 (57.1%) patients were controlled in group A against 1 (9.1%) in group B.5 (35.7%) patients were partially controlled in group A against 8 (72.2%) in group B.1 (7.1%) patient was uncontrolled in group A against 2 (18.2%) in group B. Thus, children in Group A who had an exacerbation following viral URTI as a trigger were better controlled at 4 weeks as compared to those in Group B (p=0.045-Significant).\  At 3 months out of these cases,9 (64.3%) patients were controlled in group A against 5 (45.5%) in group B.4 (28.6%) patients were partially controlled in group A against 3 (27.3%) in group B.1 (7.1%) patient was uncontrolled in group A against 3 (27.3%) in group B. Thus, at 3 months, there was no statistically significant difference in the control status of patients with viral URTI as a trigger in between the two treatment groups.  2 patients out of 28 in group A had allergic rhinitis whereas 1 out of 26 patients in group B had it. At 4 weeks, out of these cases. 2 (100.0%) patients were controlled in group A against none (0.0%) in group B. 1 (100%) Patient in Group B was uncontrolled. P-Value was 0.333, suggesting a statistically non-significant difference in control of asthma symptoms in patients having allergic rhinitis as a co-morbid allergic disorder between two groups at 4 weeks of treatment.  At 3 months, out of these cases. 2 (100.0%) patients were controlled in group A against none (0.0%) in group B. 1 (100%) Patient in Group B was partially controlled. P-Value was 0.333, suggesting a statistically non-significant difference in control of asthma symptoms in patients having allergic rhinitis as co-morbid allergic disorder between two groups at 3 months of treatment.
 The goal of asthma treatment is to keep symptoms well-controlled and future risk reduction of exacerbations, fixed airflow limitation & side effects of treatment. Out of 28 patients of Group A, 9 were asymptomatic & 19 were symptomatic at 4 weeks of treatment.10 were asymptomatic & 18 were symptomatic at 3 months of treatment. P-Value was 0.09 suggesting no significant change/improvement in control of asthma symptoms at 3months than at 4 weeks in children treated with oral montelukast. Out of 26 patients of Group B, 6 were asymptomatic & 20 were symptomatic at 4 weeks of treatment.17 were asymptomatic & 9 were symptomatic at 3 months of treatment. P-Value was 0.046 suggesting a statistically significant improvement in control of asthma symptoms at 3 months than at 4 weeks in children treated with inhaled budesonide.
Discussion
Inhaled steroids & oral montelukast are both established therapies for control of mild persistent childhood asthma, but montelukast has the ease of administering once-daily tablet orally and does not require skills or special instructions to be followed as for inhaled budesonide. There was statistically insignificant difference in clinical symptoms of asthma between two treatment groups at 4 weeks of treatment. In patients on inhaled budesonide, although the day and night-time symptoms were relieved to a similar extent as in patients on montelukast, but the need for relievers was much less and improvement in activity was much more in patients on inhaled budesonide at 4 weeks of follow-up . At 4 weeks of regular treatment, asthma symptoms of children on oral montelukast were better controlled than those on inhaled budesonide (statistically significant: p-value was 0.039) . These findings were similar to those in the study by Lucie Blais et al.11 which suggested that the risk of exacerbations was significantly higher in the Inhaled corticosteroids than the leukotriene receptor antagonist group at 4 weeks of treatment11. At 3 months of treatment, patients on inhaled budesonide required significantly fewer reliever medications and there were statistically significant lesser episodes of night awakening due to asthma symptoms. The day-time symptoms were significantly relieved and improvement in activity was much more in patients on inhaled budesonide at 3 months of follow-up. Though it was not statistically considered as 'Symptomatic'. On statistical analysis, comparing clinical efficacy of oral montelukast at 4 weeksand3 months, the p-value for symptom control was 0.09, suggesting no significant change/improvement in control. On statistical analysis, comparing clinical efficacy of inhaled budesonide at 4 weeksand3 months, the p-value was 0.046 suggesting a statistically significant improvement in control at 3months than at 4 weeks in patients on inhaled budesonide. This suggests that montelukast has a relatively rapid onset of symptom control in children with asthma but has lesser clinical efficacy as compared to inhaled budesonide. Inhaled budesonide takes relatively more time to achieve symptom control, but has more clinical efficacy than montelukast. This is because montelukast has antiinflammatory effect only against inflammationmediated through leukotrienes whereas Inhaled corticosteroids have a versatile anti-inflammatory activity which down-regulates most pathways involved in the synthesis of cytokines and other inflammatory mediators, resulting in better control and higher clinical efficacy15. Conclusion At 4 weeks of regular treatment, symptoms of children with mild persistent childhood asthma on oral montelukast were better controlled than those on inhaled budesonide. In patients on inhaled budesonide, the need of reliever medications was much less and improvement in activity was much more at 4 weeks of follow-up. At 3 months of regular treatment, there was statistically non-significant difference in the control status between two groups. However in terms of absolute numbers, more children on inhaled budesonide were controlled on their asthma symptoms than those on oral montelukast. Patients on inhaled budesonide required significantly less reliever medications and had lesser episodes of night awakening due to asthma symptoms. Also, more number of children on inhaled budesonide had improvement in their day-time symptoms and activity than those on oral montelukast.
